# OnCo record inotuzumab-ozogamicin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/inotuzumab-ozogamicin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "inotuzumab-ozogamicin" ;
  schema:name "Inotuzumab ozogamicin"@en ;
  schema:description "Inotuzumab ozogamicin is an antibody carrying a DNA-cutting toxin to CD22 on leukaemia cells. It gets far more relapsed ALL patients into remission than chemotherapy and bridges them to transplant."@en ;
  schema:url <https://onco.cc/drugs/inotuzumab-ozogamicin/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Inotuzumab_ozogamicin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3799041> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Inotuzumab%20ozogamicin> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Besponsa" ;
  onco:approval "US 2017: Relapsed/refractory CD22+ B-ALL, adults", "US 2024: Paediatric patients ≥1 year with relapsed/refractory CD22+ B-ALL" ;
  onco:related <https://onco.cc/biomarkers/cd22-expression/> ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/all-paediatric-relapsed/>, <https://onco.cc/cancers/all-paediatric-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd22/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:terms <https://onco.cc/terms/payload/>, <https://onco.cc/terms/linker/> ;
  onco:trials <https://onco.cc/trials/ino-vate/>, <https://onco.cc/trials/nct05748171/> .